Kalderos, a Chicago, IL-based creator of a drug discount management solution, secured $28m in Series B funding.
Backers included Bain Capital Ventures and Mercato Partners.
The company intends to use the funds to expand its capabilities to solidify its point-of-sale solution, expand to directly support patient and other discount types, and explore other financial exchanges in healthcare which would benefit from dedicated infrastructure.
Led by Jeremy Docken, CEO and co-founder, Kalderos provides a SaaS based drug discount management solution, which identifies, checks, and resolves non-compliance. Using models and machine learning processes, Kalderos detects inconsistencies overlooked by current methods, providing material benefits by eliminating waste. The company’s solutions have already served stakeholders throughout the healthcare system, including providers. Recently, Kalderos launched its provider-facing Review platform to support 340B-covered entities in their claims review process and is also planning for the launch of its 501(c)(3) nonprofit arm which, once operational, aims to support patients directly by ensuring those patients who need lifesaving medications can afford them.